Pazopanib Pregnancy and Breastfeeding Warnings

Pazopanib is also known as: Votrient

Pazopanib Pregnancy Warnings

This drug should be used during pregnancy only if clearly needed and the benefit outweighs the risk. AU TGA pregnancy category: D US FDA pregnancy category: D Comments: Women of childbearing potential should be advised to use adequate contraception during drug therapy and for 4 weeks after therapy, and avoid becoming pregnant while receiving drug treatment.

Animal studies revealed evidence of teratogenicity, embryotoxicity, embryolethality, fetotoxicity, maternal toxicity, reduced maternal and fetal weight, cardiovascular malformations, incomplete or absent ossification, increased pre- and post-implantation loss, early resorptions, and abortifacient properties. There are no controlled data in human pregnancy. The drug may impair fertility in humans. Animal reproductive studies have shown reduced fertility, decreased corpora lutea, and increased incidence of ovarian cysts and atrophy in females. Reductions in sperm production rates, sperm motility, epididymal and testicular sperm concentrations, atrophy and degeneration of the testes have been observed in males. AU TGA pregnancy category D: Drugs which have caused, are suspected to have caused or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. These drugs may also have adverse pharmacological effects. Accompanying texts should be consulted for further details. US FDA pregnancy category D: There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Pazopanib Breastfeeding Warnings

Use is not recommended and a decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother. Excreted into human milk: Unknown Excreted into animal milk: Data not available Comments: The effects in the nursing infant are unknown.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide
(web2)